Treatment of Advanced or Metastatic NSCLC with MET Exon 14 Skipping Mutation
Non-small cell lung cancer (NSCLC) harbouring a MET exon 14 (METex14) skipping mutation represents a molecularly distinct subgroup in advanced and metastatic disease. Identification of this alteration through molecular testing is central to guiding therapy.
Clinical Scenario
MET exon 14 skipping mutations occur in approximately 3% to 4% of patients with lung adenocarcinoma and around 2% of patients with other NSCLC histologies. The presence of this mutation is associated with responsiveness to oral HGF receptor (c-Met) tyrosine kinase inhibitors, distinguishing this subgroup from other NSCLC populations.
Treatment Approach
For patients with advanced or metastatic NSCLC and a confirmed METex14 skipping mutation, evidence supports the use of targeted oral c-Met inhibitor therapy. Preferred and alternative agent options — including sequencing considerations for patients not previously treated with specific agents — are detailed in the full structured protocol.
Full regimen, agent selection, and sequencing available in the protocol below.
References
- MET exon 14 skipping mutations occur in 3% to 4% of patients with lung adenocarcinoma and approximately 2% of patients with other NSCLC histologies.
- The presence of METex14 skipping mutation is associated with responsiveness to oral HGF receptor (c-Met) TKIs.
- These are also recommended as subsequent therapy options, if the patient was not previously treated with capmatinib, tepotinib, or crizotinib.
View source ↗